The K + channel KCNQ1 has been proposed as a tumor suppressor in colorectal cancer (CRC). We investigated the molecular mechanisms regulating KCNQ1:β-catenin bidirectional interactions and their effects on CRC differentiation, proliferation, and invasion. Molecular and pharmacologic approaches were used to determine the influence of KCNQ1 expression on the Wnt/β-catenin signaling and epithelial-to-mesenchymal transition (EMT) in human CRC cell lines of varying stages of differentiation. The expression of KCNQ1 was lost with increasing mesenchymal phenotype in poorly differentiated CRC cell lines as a consequence of repression of the KCNQ1 promoter by β-catenin:T-cell factor (TCF)-4. In welldifferentiated epithelial CRC cell lines, KCNQ1 was localized to the plasma membrane in a complex with β-catenin and E-cadherin. The colocalization of KCNQ1 with adherens junction proteins was lost with increasing EMT phenotype. ShRNA knock-down of KCNQ1 caused a relocalization of β-catenin from the plasma membrane and a loss of epithelial phenotype in CRC spheroids. Overexpression of KCNQ1 trapped β-catenin at the plasma membrane, induced a patent lumen in CRC spheroids, and slowed CRC cell invasion. The KCNQ1 ion channel inhibitor chromanol 293B caused membrane depolarization, redistribution of β-catenin into the cytosol, and a reduced transepithelial electrical resistance, and stimulated CRC cell proliferation. Analysis of human primary CRC tumor patient databases showed a positive correlation between KCNQ1:KCNE3 channel complex expression and disease-free survival. We conclude that the KCNQ1 ion channel is a target gene and regulator of the Wnt/β-catenin pathway, and its repression leads to CRC cell proliferation, EMT, and tumorigenesis.
The K + channel KCNQ1 has been proposed as a tumor suppressor in colorectal cancer (CRC). We investigated the molecular mechanisms regulating KCNQ1:β-catenin bidirectional interactions and their effects on CRC differentiation, proliferation, and invasion. Molecular and pharmacologic approaches were used to determine the influence of KCNQ1 expression on the Wnt/β-catenin signaling and epithelial-to-mesenchymal transition (EMT) in human CRC cell lines of varying stages of differentiation. The expression of KCNQ1 was lost with increasing mesenchymal phenotype in poorly differentiated CRC cell lines as a consequence of repression of the KCNQ1 promoter by β-catenin:T-cell factor (TCF)-4. In welldifferentiated epithelial CRC cell lines, KCNQ1 was localized to the plasma membrane in a complex with β-catenin and E-cadherin. The colocalization of KCNQ1 with adherens junction proteins was lost with increasing EMT phenotype. ShRNA knock-down of KCNQ1 caused a relocalization of β-catenin from the plasma membrane and a loss of epithelial phenotype in CRC spheroids. Overexpression of KCNQ1 trapped β-catenin at the plasma membrane, induced a patent lumen in CRC spheroids, and slowed CRC cell invasion. The KCNQ1 ion channel inhibitor chromanol 293B caused membrane depolarization, redistribution of β-catenin into the cytosol, and a reduced transepithelial electrical resistance, and stimulated CRC cell proliferation. Analysis of human primary CRC tumor patient databases showed a positive correlation between KCNQ1:KCNE3 channel complex expression and disease-free survival. We conclude that the KCNQ1 ion channel is a target gene and regulator of the Wnt/β-catenin pathway, and its repression leads to CRC cell proliferation, EMT, and tumorigenesis.
KCNQ1 | β-catenin | colon cancer | epithelial-mesenchymal transition | adherens junctions T he development of colorectal cancer (CRC) is determined by multiple factors including ion transport (1, 2) . During the last 10 years, evidence for the role of K + channels in the development and growth of tumors has greatly expanded. Voltage-gated K + channels (Kv) are involved in the proliferation of many cell types, including intestinal cells. Although the recent literature clearly demonstrates that Kv channels are among the targets of interest in the fight against cancer (3) (4) (5) , the specific role of each Kv channel in tumorigenesis and the molecular mechanisms involved are unknown. This is notably the case of the KCNQ1 K + channel. The KCNQ1 gene has recently been identified as a tumor suppressor in mouse and human CRC tissues (6) . KCNQ1 deficiency in mice caused rectal adenomatous hyperplasia and progression to adenocarcinoma. A loss of imprinting of KCNQ1 has been described in CRC (7) . However, the functional and molecular events linking KCNQ1 and CRC progression remain unclear. One obvious pathway, which may interact with KCNQ1, is Wnt/ β-catenin signaling, which plays a key role in driving early embryogenesis, as well as intestinal homeostasis and stem cell renewal in the intestinal mucosa epithelia (8) . Deregulation of the β-catenin signaling axis is present in more than 80% of CRCs. This can lead to β-catenin accumulation in the cytosol, increased nuclear translocation of activated β-catenin, interactions with members of the T-cell factor (TCF) family, and stimulation of β-catenin-dependent gene expression, leading to increased cell proliferation and growth (9) . In CRC cells, excessive nuclear accumulation of β-catenin was shown to increase the transcription of KCNQ1OT1 (10), a long noncoding RNA known to negatively regulate KCNQ1 expression. A possible link between β-catenin and ion channels in CRC has never been established. In this study, we demonstrate a bidirectional interaction between KCNQ1 and β-catenin regulating CRC cell differentiation processes. We also demonstrate that KCNQ1 is a target gene of β-catenin:TCF4, and that the expression, as well as the ion channel function, of KCNQ1 modulate epithelial phenotype. Moreover, KCNQ1 expression and its regulatory channel subunit KCNE3 (11) were correlated with better CRC patient survival.
Results
Loss of KCNQ1 Is Associated With Mesenchymal Phenotype in CRC Cells. In normal colonic epithelium, KCNQ1 drives Cl − secretion and generates the resting membrane potential (12, 13) . Low expression of KCNQ1 has been correlated with CRC development in APC mouse models, but the function of the channels remains unknown (6) . Using Western blotting, we compared the expression of KCNQ1 protein in six CRC cell lines of varying differentiation states and observed a high expression in
Significance
The K + channel KCNQ1 has been proposed as a tumor suppressor in colorectal cancer (CRC), but nothing is known about its regulatory role in early disease stages. KCNQ1 is a target gene of Wnt/β-catenin, which is tonically activated in CRC. We demonstrate a bidirectional interaction between KCNQ1 and β-catenin as a key regulator of CRC cell differentiation, proliferation, and invasion. KCNQ1 stabilizes β-catenin at adherent junctions to maintain an epithelial phenotype. The β-catenin: T-cell factor (TCF)-4 transcriptional pathway directly represses KCNQ1 expression, and the loss of KCNQ1 was associated with an epithelial-mesenchymal transition. The KCNQ1:KCNE3 ion channel complex expression in primary tumors was correlated with good survival outcome for patients with CRC. KCNQ1 is a potential early prognostic biomarker for CRC.
well-differentiated cells (HT29cl.19A and HT29) and a low expression in moderate to poorly differentiated cells (DLD-1, HCT116, SW480, SW620) (Fig. 1A) . This observation was confirmed by quantitative PCR showing a decreasing expression of KCNQ1 mRNA with increasing mesenchymal phenotype (Fig.  1B) . A high KCNQ1 expression was associated with strong expression of the epithelial marker E-cadherin and low expression of the mesenchymal marker N-cadherin. The converse was also found: a low expression of KCNQ1 was associated with a low expression of E-cadherin and a high expression of N-cadherin (Fig. 1A) . Thus, it appears that KCNQ1 expression decreases with epithelial-to-mesenchymal transition in CRC cells. The subcellular localization of KCNQ1 was investigated using confocal immunofluorescence microscopy both in CRC cells of varying epithelial-to-mesenchymal transition (EMT) differentiation and in isolated rat colonic crypts. In the well-differentiated HT29cl.19A cells, as well as in rat crypt cells, the expression of KCNQ1 was colocalized with β-catenin at the plasma membrane ( Fig. 1 C and D) . In contrast, KCNQ1 was undetectable in the mesenchymal phenotypic SW480 cells, which showed high abundance of β-catenin in the cytosol (Fig. 1C) . The colocalization between KCNQ1 and β-catenin was confirmed by van Steensel's analysis (14) in both HT29cl.19A cells and crypt cells in which a similar Pearson's coefficient value was found (SI Appendix, Fig. S1 A and B) .
Activation of β-Catenin Causes Direct Transcriptional Repression of KCNQ1. We investigated the role of β-catenin in KCNQ1 expression, using a pharmacologic approach. β-catenin activity was increased using two inhibitors of glycogen synthase kinase 3β (GSK3β): AR-A014418 (AR-A) and GSK3-inhibitor X (GSK3-iX). The activation of β-catenin and its translocation into the nuclear fraction after inhibition of GSK3β was verified in HT29cl.19A cells (SI Appendix, Fig. S2 ). Activation of β-catenin reduced KCNQ1 total abundance in HT29cl.19A cells by 60% ( Fig. 2A) and reduced the colocalization of KCNQ1 with β-catenin at the plasma membrane (SI Appendix, Fig. S3 ). Similar effects of pharmacologic agents were observed in HT29 cells (SI Appendix, Fig. S4 ). In addition to the pharmacologic approach, we also used a plasmid expressing a truncated form of β-catenin (β-catΔN87) to constitutively activate β-catenin. HT29cl.19A and HT29 cells transfected with activated β-catenin showed a loss of KCNQ1 and a redistribution of β-catenin from the plasma membrane into the cytosol (SI Appendix, Fig. S5 ). Chromatin immunoprecipitation (ChIP) and luciferase assays were performed to determine the effects of β-catenin activation on KCNQ1 transcription. We chose SW480 cells because of their high constitutive expression of β-catenin. Treatment with GSK3-iX to increase β-catenin activation resulted in enhanced recruitment of β-catenin and TCF4 proteins to the KCNQ1 promoter ( Fig. 2 B and C) . Furthermore, the luciferase assay showed that the KCNQ1 reporter transcriptional response was reduced in CHO cells treated with GSK3-iX compared with vehicle-treated control (Fig. 2D) . To confirm the role of TCF4 in the control of KCNQ1 expression, DLD-1 and SW480 cells, which show low constitutive KCNQ1 expression, were transfected with a plasmid carrying a dominant negative mutant of TCF4 (hΔNTCF4), which cannot form a complex with β-catenin. This experiment revealed that the expression of KCNQ1 was restored in the presence of hΔNTCF4 in both cell lines ( Fig. 2 E and F) . Taken together, these data provide a molecular mechanism by which the activated Wnt/β-catenin pathway inhibits KCNQ1 protein expression via direct binding of a repressive β-catenin:TCF4 complex at the KCNQ1 promoter.
KCNQ1 Modulates β-Catenin Interactions at Adherens Junctions. In situ proximity ligation assay (PLA) revealed that KCNQ1 binds to both E-cadherin and β-catenin, which are markers of adherens junctions (AJ). In rat colonic crypts, KCNQ1 and β-catenin were observed by PLA to be in close association (Fig. 3A and SI Appendix, Fig. S6 ). PLA dots were mainly observed at cell-to-cell contacts, and this was verified in HT29cl.19A cells, showing that KCNQ1 is a component of AJ in close contact (<40 nm) with β-catenin and E-cadherin ( Fig. 3B and SI Appendix, Fig. S6 ). Furthermore, silencing of KCNQ1 in HT29cl.19A cells using ShRNA resulted in a significant disruption to E-cadherin:β-catenin interactions (Fig. 3C ). These observations indicate the importance of KCNQ1 in maintaining AJ stability and tight junction formation. This was further demonstrated by the reduction in transepithelial electrical resistance (TEER) in HT29cl.19A cells in which KCNQ1 expression had been silenced (Fig. 3D) . Silencing of KCNQ1 also resulted in a redistribution of β-catenin from the plasma membrane to a more diffuse cytosolic location (SI Appendix, Fig. S7A ). Consistent with this observation, KCNQ1 silencing resulted in altered phosphorylation of β-catenin at specific residues that determine its subcellular distribution and stability. The level of p-S33 phosphorylation that induces the degradation of cytosolic β-catenin (15, 16) was lower in the KCNQ1 knockdown cell lines (Fig. 3E ). In contrast, phosphorylation at residues Y654 and S675, which favor the stabilization of cytosolic β-catenin and its translocation into the nucleus, was significantly increased in KCNQ1-silenced cells (Fig. 3E ). These results lend strong support for the conclusion that KCNQ1 is a pivotal regulator of β-catenin stability and subcellular distribution. As a corollary, the data indicate that KCNQ1 suppresses the Wnt/β-catenin signaling pathway. This was indeed shown to be the case where silencing KCNQ1 expression activated signaling intermediates of the Wnt/ β-catenin pathway, increasing the expression of p-AKT, p-GSK-3-β, cyclin D-1, cJun, and Met (SI Appendix, Fig. S7 B and C).
KCNQ1 Expression Suppresses Mesenchymal Features in CRC Spheroids.
Knock-down of KCNQ1 induced a significant increase in mesenchymal markers (claudin-1, β-catenin, and N-cadherin), with a concomitant reduction in epithelial markers (ZO-1 and E-cadherin) (Fig. 4A) . When grown on a 3D matrix, highly differentiated CRC cells such as HT29cl.19A underwent cystogenesis and generated spheroid structures. HT29cl.19A spheroids showed characteristic accumulation of F-actin at the apical membrane, β-catenin lateral staining, a patent central lumen, and welldefined adherens junctions (Fig. 4B ). Knock-down of KCNQ1 significantly impaired the ability of HT29cl.19A cells to form spheroids, and the frequency of lumen formation was reduced from 80% to 20% (Fig. 4B) .
We examined the effects of overexpression of KCNQ1 in an intermediate EMT cell line HCT116 with low endogenous expression levels of KCNQ1. KCNQ1 construct expression in HCT116 cells led to an increase in epithelial markers (ZO-1 and E-cadherin) and a decrease in mesenchymal markers (β-catenin and N-cadherin) (Fig. 5A ). The overexpression of KCNQ1 in HCT116 cells restored the ability of this moderately differentiated CRC cell line to form spheroid structures, and the frequency of lumen formation was increased from 19% to 62%. (Fig. 5B) . Collectively, these results demonstrate that KCNQ1 is required to maintain a well-differentiated epithelial phenotype.
KCNQ1 Ion Channel Function and Membrane Voltage Modulate CRC
Phenotype and β-Catenin Subcellular Distribution. The function of KCNQ1 as an ion channel is essential to maintain a hyperpolarized negative membrane voltage in colonocytes (11, 13) . We observed that KCNQ1 overexpression in HCT116 cells induced a redistribution of β-catenin and KCNQ1 at the plasma membrane ( Fig. 6A ) and membrane hyperpolarization (Fig. 6B ). The membrane hyperpolarization was exclusively generated by KCNQ1 channels, as the change in membrane potential was inhibited by the KCNQ1 selective channel blocker chromanol 293B (Fig. 6B ). The inhibition of outward K + current flow through KCNQ1 channels will produce a membrane depolarization. The effects of membrane depolarization on KCNQ1 and β-catenin (E ) Western blot and densitometry analysis of different phosphorylated β-catenin residues in HT29cl.19A KCNQ1 knockdown cells (n = 3-5. *P < 0.05; **P < 0.01; ***P < 0.001). cellular distribution was investigated in HT29cl.19A cells. Membrane depolarization was produced by two methods: collapsing the electrochemical gradient for K + by exposure to high extracellular K + and inhibiting outward K + currents with a specific KCNQ1 ion channel blocker. Membrane depolarization triggered by exposing the cells to high external K + (predicted membrane potential from the Nernst equation: +2 mV), caused a rapid (within 5 min) redistribution of KCNQ1 and β-catenin from the plasma membrane into the cytosol (Fig. 6C) . Blocking KCNQ1 channels with chromanol 293B (C293B) produced a similar cytosolic redistribution of KCNQ1 and β-catenin (Fig. 6D) . Transepithelial electrical resistance is determined mainly by cell-cell adhesion properties of tight junctions. Two selective blockers (C293B and HMR) of KCNQ1 ion channels produced a decrease in ZO-1 expression and a reduced TEER over the course of 10 d of cell culture (SI Appendix, Fig. S8 ). Taken together, these data demonstrate that the function of KCNQ1 as an ion channel is essential for KCNQ1 and β-catenin interaction and the formation of a polarized epithelium.
KCNQ1 Suppresses Proliferation and Invasion of CRC Cells. Given the modulation of β-catenin by KCNQ1, we hypothesized that KCNQ1 expression could modulate CRC cell proliferation. Treatment of HT29cl.19A cells with GSK3-iX to activate β-catenin and decrease KCNQ1 expression resulted in an increase in cell proliferation (SI Appendix, Fig. S9A ). Inhibition of the KCNQ1 channel with C293B also resulted in an increase in proliferation (SI Appendix, Fig. S9B ). Conversely, increasing KCNQ1 activity by transfection of DLD-1 cells with hΔN-TCF4 resulted in a decrease in cell proliferation (SI Appendix, Fig. S9C ). Treatment of hΔN-TCF4 transfected DLD-1 cells with C293B to block KCNQ1 channels rescued the proliferative capacity (SI Appendix, Fig. S9D ). Overexpression of KCNQ1 in HCT-116 cells resulted in a decreased proliferation (SI Appendix, Fig. S9E ). To evaluate the role of KCNQ1 in cell invasion, cells were subjected to a 3D Matrigel invasion assay. HCT116 cells overexpressing the KCNQ1 construct showed a lower rate of invasion compared with wild-type cells of low KCNQ1 expression (SI Appendix, Fig. S10 ). These data demonstrate that KCNQ1 channels act to repress proliferation and invasion of CRC cells. The KCNQ1 functional channel complex in colon is composed of the KCNQ1 pore-forming unit and a KCNE3 regulatory subunit. In a cohort of 355 human primary colon tumor samples, Kaplan Meier and log rank test analysis demonstrated that CRC relapsefree survival was significantly higher for patients with high KCNQ1 (Fig. 7A) and high KCNE3 mRNA expression (Fig. 7B) . TCF4, which we have shown to suppress the KCNQ1 promoter, was inversely correlated with KCNQ1 expression in these patients (SI Appendix, Fig. S11 ). High TCF4 expression was significantly correlated with low patient survival probability (Fig.  7C) . Although KCNQ1 was correlated with patient survival, we found no significant correlation between KCNQ1 expression and tumor stage (SI Appendix, Table S1 ).
Discussion
Our study demonstrates that KCNQ1 is a target gene for the Wnt/β-catenin pathway. We also uncovered a function of KCNQ1 in regulating β-catenin activity at the plasma membrane. The loss of KCNQ1 promotes the disruption of cell-cell contact, contributing to EMT, cell proliferation, and invasion. The function of KCNQ1 as an ion channel appears to be involved in these processes. We describe the molecular mechanisms of KCNQ1:β-catenin bidirectional interactions and a signaling pathway for the tumor suppressor activity of KCNQ1 in CRC. A number of studies have linked K + channel deregulation to carcinogenesis (4, 5) , but the underlying molecular mechanisms have remained largely unknown. In this study, we demonstrate a positive correlation between high KCNQ1 expression and CRC cell epithelial phenotype and patient survival in primary stage CRC. The characterization of signaling pathways regulating ion channel expression in cancers is an open question, and very few cases, including the overexpression of the K + channel oncogene EAG1 (17) , have been documented so far. Here we demonstrate that β-catenin:TCF4 signaling can regulate the expression of KCNQ1 at the KCNQ1 promoter in CRC cells.
Wnt/β-catenin signaling represents the main pathway involved in CRC initiation and progression (8) . In this study, we showed that differential KCNQ1 expression in CRC cell lines of varying EMT phenotype is associated with changes in β-catenin activation and subcellular distribution. In well-differentiated CRC cell lines, both KCNQ1 and β-catenin were colocalized at the plasma membrane, whereas in poorly differentiated, mesenchymal phenotype CRC cells, loss of KCNQ1 was associated with a cytoplasmic and nuclear redistribution of β-catenin from the plasma membrane. These observations raise the possibility that KCNQ1 and β-catenin coexist in a signaling complex to regulate β-catenin subcellular localization and the development of EMT. Activation of β-catenin using either pharmacologic inhibitors of GSK3β or a constitutively activated β-catenin construct repressed KCNQ1 expression in well-differentiated CRC cell lines, suggesting that β-catenin translocation to the nucleus promotes KCNQ1 repression. β-catenin is a coactivator of the transcription factor family TCF/LEF (T-cell factor/lymphoid enhancer binding factor), and we showed that KCNQ1 expression was repressed by β-catenin:TCF4 binding to the KCNQ1 promoter. The key role of TCF4 in modulating KCNQ1 expression was further supported by the finding that molecular inhibition of TCF4 activity restored the expression of KCNQ1 in poorly differentiated CRC cell lines. Our study provides solid evidence that KCNQ1 is a target gene of β-catenin signaling and a regulator of the Wnt pathway, which could explain the repression of KCNQ1 observed in the human CRC patient cohort.
We demonstrated that KCNQ1 is associated with β-catenin and E-cadherin at the plasma membrane in well-differentiated CRC cell lines. The complex formed by β-catenin and E-cadherin is constitutive proteins forming adherens junctions in epithelia (18) . Our study unveils a key role for KCNQ1 in preserving adherens junctions and transepithelial electrical resistance through the control of β-catenin activity and its subcellular localization. In support of such a role, we found that KCNQ1 expression influenced the β-catenin phosphorylation state. Silencing of KCNQ1 decreased S33 β-catenin phosphorylation, which enhances β-catenin stability (19) . KCNQ1 knockdown increased β-catenin phosphorylation at residues Tyr654 and Ser675, which enhance β-catenin-induced transcription (20, 21) . Phosphorylation at Tyr654 reduces the β-catenin binding to E-cadherin (22, 23) , which promotes the association of β-catenin with transcription factors in the nucleus (20) . In addition, P-Ser675 protects β-catenin from proteasomal degradation (24, 25) . These results further indicate that KCNQ1 anchors β-catenin at the plasma membrane, stabilizing AJs and promoting cell-cell contact. This role for KCNQ1 is supported by our findings that KCNQ1 silencing induced a loss of spheroid organization and lumen formation in CRC 3D cultures. We propose a model in which KCNQ1 is essential for epithelium integrity by stabilizing AJ proteins, repressing EMT by retaining β-catenin at the plasma membrane, thus limiting β-catenin: TCF4 transcriptional activation of proliferative genes. In addition, our results suggest this function depends, in part, on the regulation of the membrane potential by the channel. Electrophysiological analyses in many cancer cell types have shown that membrane depolarization favors cell proliferation (26) . We demonstrated that KCNQ1 maintains a hyperpolarized Vm in CRC cells, and experimental maneuvers designed to collapse the outward K + currents through KCNQ1 channels disrupted the normal KCNQ1:β-catenin interaction at the plasma membrane and produced a more mesenchymal phenotype. We conclude that the functional endpoint of the bidirectional KCNQ1:β-catenin interaction is the regulation of proliferative and invasive potency of CRC cells.
The loss of KCNQ1 expression is associated with poor survival in patients with CRC liver metastases (6) , and a recent study has shown that low KCNQ1 mRNA expression correlates with poor disease-free survival in stage II colon cancers (27). In our analysis of human primary tumors from patients with stage I to IV disease, we observed that high expression of KCNQ1 was significantly associated with a better patient survival outcome. TCF4 expression showed an inverse correlation with survival outcome in our patient cohort that is consistent with its role in repressing KCNQ1. Intriguingly, we also found a direct correlation between survival outcome and high expression of KCNE3, the regulatory subunit of the KCNQ1 ion channel in human colon. We also found the KCNQ1 expression, although being significantly associated with survival, is independent of tumor stage. This increases the attractiveness of KCNQ1:KCNE3 as a predictive marker and a therapeutic target in CRC.
Taken together, our study demonstrates a bidirectional interaction between KCNQ1 and β-catenin, which controls both their expression and subcellular localization to modulate CRC cell phenotype, proliferation, and invasion. received from the University of Nice Sophia-Antipolis). Animals were killed by lethal intraperitoneal injection of pentobarbital. The colon was removed by dissection, and colonic crypts were isolated as previously described in ref. 12 .
Plasmid Transfection and ShRNA Transduction. Two stable KCNQ1 shRNA knock-down cell lines were engineered using two different DNA sequences (SI Appendix, Materials and Methods) The double-stranded DNA sequences were inserted in the mammalian expression vector pSuperRT Puro, a derivative of the pPRIG series. Transduction experiments were performed as previously described (28, 29) . Cells were transiently transfected using lipofectamine 2000 (Invitrogen), according to the manufacturer's recommendation. DLD-1 and SW480 cells were transfected with 2 μg hΔN-TCF4 plasmid (30) . HT29cl.19A and HT29 were transfected in suspension with 2 μg β-catΔN87 plasmid (31) . KCNQ1 transduction of HTC116 cells was performed as described previously (32) . More details are given in SI Appendix, Materials and Methods.
Transepithelial Electrical Resistance. HT29cl.19A cells were grown on semipermeable supports (Merck Millipore), and TEER was measured in triplicate with an EVOM electrometer (WPI), using triplicates for each measurement every 2 d for 10 d. More details are given in SI Appendix, Materials and Methods.
Chromatin Immunoprecipitation. ChIP was carried out using a ChIP-IT High Sensitivity Kit (Active Motif), as previously described (33) . More details are provided in SI Appendix, Materials and Methods.
Immunoblotting and Immunofluorescence. Whole-cell lysates were prepared and subjected to 8% SDS/PAGE before proteins being transferred onto a nitrocellulose membrane. Membranes were probed with the primary antibody overnight at 4°C. Reactive proteins were developed with HRPconjugated secondary antibody and visualized with chemiluminescence according to the manufacturer's protocol (GE Healthcare). Immunostaining was performed as previously described (12) . Bound antibodies were detected using rabbit anti IgG Alexa 488 (Invitrogen). Image acquisition was performed using a Zeiss LSM710 laser scanning confocal microscope.
In situ Proximity Ligation Assay. The DuoLink PLA (Olink Bioscience) was used to detect interactions among KCNQ1, β-catenin, and E-cadherin. HT29cl.19A cells were seeded on poly-Lysine (40 μg/mL)-coated microscope slides. CRC cells and isolated rat colonic crypts were fixed with paraformaldehyde 4% and permeabilized with triton ×100 (0.05%). Cells were immunolabeled with primary antibodies anti KCNQ1, Kv7.1 (1:100) and anti β-catenin (1:100), or anti E-cadherin (1:100) for 1 h at 37°C. The secondary antibodies with attached PLA probes were supplied in the Duolink kit. Cellular PLA images were captured using an inverted Zeiss Axio Observer Z1 microscope (Zeiss). PLA dots per cells were quantified using Image J software.
Luciferase Reporter Assay. CHO cells were plated at 2 × 10 4 cells/well in 96-well plates. One day after plating, the cells were washed once with PBS and transfected with either LightSwitch GoClones KCNQ1 reporter (Active Motif), LightSwitch GAPDH Promoter Control (positive control; Active Motif), or LightSwitch Random Promoter Control 1 (negative control) (Active Motif), using FuGENE HD transfection reagent (Promega Corporation). After 24 h, transfected cells were treated with 40 nM GSK3-iX (Merck Millipore) for another 24 h. Luciferase activities were measured using the LightSwitch Luciferase Assay Kit and LightSwitch Assay Substrate optimized for use with RenSP luciferase, using one-step reagent addition (Active Motif).
Statistical Analysis. Mann-Whitney or Kruskal-Wallis nonparametric test were applied to compare significance between two or more groups, as appropriate. The frequency of lumen formation in HT29cl.19A and HCT116 spheroids was analyzed using Fisher's exact test. Values of n number of experiments are given as mean ± SEM. A P value <0.05 was considered statistically significant. 
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SI Materials and Methods
Antibodies
The following antibodies were purchased. Cell Signaling Technology: Phospho-β- Matrigel were seeded in 8-well coverglass chambers (Nalge Nunc) precoated with 100% GFR Matrigel (for 30min at 37°C). Cells were fed every 2 days and grown for 10 days.
ShRNA transduction
The DNA sequences of KCNQ1 ShRNA are as follow: 5'-GTA GAT CTT CCA GGT GGA GTT TTT TGG AAA-3' (shQ1-1) and 5'-GAT CCC GTC TTT GCC ATC TCC TTC TTT GCT CGA GCA AAG AAG GAG ATG GCA AAG ATT TTT TGG AAA-3' (shQ1-2).
Plasmid transduction
cDNA coding sequence of KCNQ1 was subcloned into the modified mammalian expression vector pPRIG-eGFP where eGFP was exchanged for puromycin resistance sequence in order to generate pPriPu vector. Retroviruses were produced transfecting HEK 293T cells with pPriPu/KCNQ1, pCMV-VSVG, pCMVgag-pol plasmids, using the classic calcium phosphate transfection technique.
Replication-defective retroviruses were recovered in the culture medium between 48h post-transfection. This retroviral supernatant was filtered through sterile 0.45 µm filters, then added directly to HTC 116 cells in the presence of 4 µg/ml polybrene to enhance retroviral transduction efficiency. 3 days later, puromycin was added in fresh medium to start selection of transduced cells.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) in SW480 cells was carried out using ChIP-IT ® High Sensitivity Kit (Active Motif, USA) as previously described (33) .
The name and sequences of the primers, cycles and annealing temperature for each pair are listed in Table S2 . Table S3 . Table S3 . Gene-specific primer sequences for qPCR. 
Matrigel drops invasion assay
HCT 116 control cells and HCT116 expressing KCNQ1 (4X10 5 cells) were included in 40% growth-factor-reduced Matrigel drops and incubated in 10% FBS at 37°C, 5% CO 2 in an incubator associated to a time laps microscope (Zeiss).
Images were recorded every hour for 60 hours.
Kaplan-Meier analysis
Kaplan-Meier analysis of relapse-free patient survival in 286 primary colon tumors was carried out using the R2 bioinformatics web tool on previously published data sets GSE14333 and GSE17538 (R2: Genomics analysis and visualization platform (http://r2.amc.nl). Median gene expression was used to stratify patients into high or low expression for each gene. P-values were calculated based on a log rank test.
Utilising the previously published colon cancer data sets GSE14333 and GSE17538 used to perform the survival analysis, we attempted to establish if there was a significant correlation between KCNQ1 expression and tumor stage.
These studies used the Affymetrix Human Genome U133 Plus 2.0 microarray to measure the colon cancer transcriptome. There are two probes (204487_s_at, 211217_s_at) for the KCNQ1 gene on this microarray platform. Gene expression values were called using the GeneChip (GC) robust multichip average method (1) and the data was quantile normalised using the Bioconductor package, affy (http://www.bioconductor.org/). For each probe, we calculated Pearson's correlation coefficient between probe expression level and tumour stage.
Van Steensel's cross correlation function
The cross-correlation function (CCF) of a dual labeling image was calculated by shifting the red image over a distance ∆x pixels in the x-direction with respect to the green image, with −25 ≤∆x ≤25. A negative value of ∆x indicates that the red image was shifted to the left, a positive value indicates a shift to the right. For each value of ∆x Pearson's correlation coefficient was calculated with a maximal value for ∆x=0.
